Start Date
December 31, 2011
Primary Completion Date
November 30, 2013
Study Completion Date
November 30, 2013
Crizotinib plus VEGF inhibitor combinations
Three combinations will be prioritized, namely crizotinib plus axitinib, crizotinib plus sunitinib and crizotinib plus bevacizumab, with a fourth combination, crizotinib plus sorafenib to be tested only if crizotinib does not combine with either axitinib and/or sunitinib. All study drugs are tablets or capsules except for bevacizumab which is parenteral (intravenous). Dosage, frequency and duration to be determined.
Crizotinib plus axitinib
Study drugs are tablets or capsules; dosage, frequency and duration to be determined.
Crizotinib plus sunitinib
Study drugs are tablets or capsules; dosage, frequency and duration to be determined.
Crizotinib plus axitinib
Study drugs are tablets or capsules; dosage, frequency and duration to be determined.
Crizotinib plus sunitinib
Study drugs are tablets or capsules; dosage, frequency and duration to be determined.
Crizotinib plus bevacizumab
Study drugs are tablets or capsules except for bevacizumab which is parenteral (intravenous). Dosage, frequency and duration to be determined.
Crizotinib plus sorafenib
Study drugs are tablets or capsules; dosage, frequency and duration to be determined.
Lead Sponsor
Pfizer
INDUSTRY